COMMUNIQUÉS West-GlobeNewswire

Sotera Health Appoints Kenneth D. Krause to the Board of Directors
16/03/2026
CLEVELAND, March 16, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company” or “Sotera Health”), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and [...]
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
16/03/2026
Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral GLP-1RAs and [...]
Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01
16/03/2026
STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
16/03/2026
- Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results - - Topline results of the global Phase 2 [...]
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
16/03/2026
- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY ® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for mid-year with [...]
Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26
16/03/2026
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, March 16, 2026 (GLOBE NEWSWIRE [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
16/03/2026
COPENHAGEN, Denmark, March 16, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up [...]
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
16/03/2026
Financing demonstrates conviction in oligomer-selective approach and follows strong preclinical data, including in vitro , in vivo and non-human primate study results, that support development candidates in Acumen’s [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting
16/03/2026
NRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and FDA Center for Drug Evaluation and Research. Minutes are [...]
Tilray Brands Enters Agreement to Acquire BrewDog’s Key U.S. Assets, Expanding Its U.S. Craft Beer Platform
16/03/2026
NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the [...]
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
16/03/2026
On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollment in the OPERA-02 [...]
Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics
16/03/2026
Financing led by The Venture Collective with participation from Merck Global Health Innovation Fund, Artis Ventures, First Spark Ventures, argenx, Droia Ventures and existing investors SANTA CRUZ, Calif., March 16, 2026 [...]
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
16/03/2026
Companies Resolve Lawsuit in Delaware BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people [...]
Weight Watchers Announces Fourth Quarter and Full Year 2025 Results
16/03/2026
2025 Total Revenue and Adjusted EBITDA 1,2 above high end of previously provided guidance Total End of Period Subscribers of 2.8 million; End of Period Clinical Subscribers of 130 thousand, up 42% year-over-year with [...]
OSE Immunotherapeutics Announces its 2026 Financial Calendar
16/03/2026
Nantes, France, March 16, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced its financial calendar for 2026. Information Date* 2025 Full-Year Financial Update and Statements [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
16/03/2026
ZUG, Switzerland, March 16, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the purchase of ordinary shares by a member of the Company’s Board of Directors. Attachments notification-of-managers-transaction [...]
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
16/03/2026
ZUG, Switzerland, March 16, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical [...]
Dvorak Botanicals Launches Low-Dose Hemp-Derived THC Gummies Focused on Mindful Consumption
16/03/2026
Atlanta, GA, March 16, 2026 (GLOBE NEWSWIRE) -- Dvorak Botanicals, a new premium hemp-derived THC brand founded by Atlanta-based entrepreneur Dane Dvorak, has launched with a focus on controlled-dose hemp products that [...]
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
16/03/2026
ZUG, Switzerland, 16 March, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in [...]

Pages